Monte Nido’s Aggressive 2021 Expansion Reflects Widening Gap Between Eating Disorder Treatment Demand and Capacity
Monte Nido & Affiliates' 2020 growth trajectory—adding five residential sites, acquiring an inpatient facility, and entering multiple new states despite pandemic disruptions—illustrates how private...
Naltrexone-Bupropion Combination Shows Promise for Methamphetamine Treatment, Addressing Critical Gap in MAT Options
Clinical trial results published in the New England Journal of Medicine demonstrating that combined naltrexone and bupropion therapy produces statistically significant improvements in methamphetamine...
Oregon’s Drug Decriminalization Initiative Tests Whether Treatment Infrastructure Can Match Policy Ambition
Oregon's groundbreaking Ballot Measure 110, which takes effect February 1 by replacing criminal penalties for drug possession with treatment pathways funded through marijuana tax...
The Digital AUD Thesis: How Monument’s $10.3M Raise Validated Alternative Pathways Beyond Traditional Addiction Treatment
When Monument announced its $10.3 million Series A funding in January 2021—bringing total capital raised to $17.8 million for a platform barely a year...
Talkspace’s $1.4B SPAC Merger Signals Digital Mental Health’s Arrival as Investable Asset Class
Talkspace's agreement to go public through a $1.4 billion merger with Hudson Executive Investment Corporation represents a watershed moment for digital mental health platforms,...
Rose Health’s Seed Funding Highlights Growing Investor Interest in Predictive Mental Health Technology
Rose Health's $1.73 million oversubscribed seed round reflects accelerating venture capital interest in predictive mental health technologies that promise early intervention capabilities, particularly as...
